Pipeline Review for Hypereosinophilic Syndrome, H1 2018 - Descriptive Drug Profiles and Key Companies Involved - ResearchAndMarkets.com

DUBLIN--()--The "Hypereosinophilic Syndrome - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders).

Companies Mentioned

  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Knopp Biosciences LLC
  • Kyowa Hakko Kirin Co Ltd
  • Stemline Therapeutics Inc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Hypereosinophilic Syndrome - Overview
  4. Hypereosinophilic Syndrome - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Hypereosinophilic Syndrome - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
  14. Bristol-Myers Squibb Co
  15. GlaxoSmithKline Plc
  16. Knopp Biosciences LLC
  17. Kyowa Hakko Kirin Co Ltd
  18. Stemline Therapeutics Inc
  19. Hypereosinophilic Syndrome - Drug Profiles
  20. benralizumab - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. dasatinib - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. dexpramipexole dihydrochloride - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. mepolizumab - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. SL-401 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. Hypereosinophilic Syndrome - Dormant Projects
  41. Hypereosinophilic Syndrome - Product Development Milestones
  42. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/xksj4w/pipeline_review?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs